Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Colorectal Neoplasms
  • Receptor, Epidermal Growth Factor

abstract

  • A retrospective analysis of the authors' 6-year experience with the combination of streptozocin plus doxorubicin in patients with islet cell carcinoma failed to confirm the high objective response rate previously reported for this regimen. There remains an urgent need for improved chemotherapeutic alternatives for patients with this disease.

publication date

  • September 15, 1999

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P

PubMed ID

  • 10491519

Additional Document Info

start page

  • 944

end page

  • 8

volume

  • 86

number

  • 6